However, we have only just begun to understand how the complex interactions between cancer cells and the immune system can be exploited to develop efficient immunotherapies.
The aims of our research are to uncover the cellular and molecular mechanisms that predispose to systemic and long-term anti-tumor immunity and the mechanisms that drive resistance to immunotherapy. In particular, we are studying how oncolytic virotherapy can be used in synergy with immunotherapy to achieve optimal immunity against tumors.
A major focus of the lab is to understand the specific role of different types of antigen-presenting cells in priming efficient anti-tumor T cell responses and how this process can be empowered to improve treatment outcomes.
We also aim to study the impact of tumor heterogeneity and tissue-specific microenvironments on the response to therapy. To address these questions we combine in vitro studies, experimental mouse models, patient material and cutting-edge technologies.
Our goal is that our research will contribute to the development of safe and more efficient treatment strategies for patients that currently do not benefit from standard therapies.
